TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14517691

Group type: EXPERIMENTAL
Intervention: Intermediate dose of IFN-alpha (2.5 MU/m² per day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: High dose of IFN-alpha (5 MU/m² per day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups (intermediate and high dose)
Number of subjects: 109
Study: 10566652

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 7676795

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study: 2178522

Group type: EXPERIMENTAL
Intervention: Sequential terbutaline (0.25 mg subcutaneously followed by another 0.25 mg subcutaneously)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single treatment (normal saline)
Number of subjects: 8
Study: 6988003

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study: 29807349

Group type: EXPERIMENTAL
Intervention: Dampening appraisals during memory recall (Study One)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amplifying appraisals during memory recall (Study One)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dampening appraisals during anticipation (Study Two)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amplifying appraisals during anticipation (Study Two)
Number of subjects: 0
Study: 27928809

Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy (tamsulosin 0.4 mg daily at night, furosemide 20mg, spironolactone 50mg in a single morning dose, potassium magnesium citrate 20Meq three times a day for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy
Number of subjects: 100
Study: 23503044

Group type: EXPERIMENTAL
Intervention: Telephone re-education (TRE) on the day before colonoscopy
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (no TRE)
Number of subjects: 605
Study: 22866288

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 20001450

Group type: EXPERIMENTAL
Intervention: Oral posaconazole suspension as antifungal prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18164144

Group type: EXPERIMENTAL
Intervention: Levodopa (400/100mg bid, Sinemet) with VBRT
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Levodopa (400/100mg bid, Sinemet)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo with VBRT
Number of subjects: 161
Study: 16041270

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 583

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 583
Study: 12486651

Group type: EXPERIMENTAL
Intervention: RITM (remifentanil and intrathecal morphine) anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl-based anesthesia (control)
Number of subjects: 24
Study: 10433573

Group type: EXPERIMENTAL
Intervention: Antibiotic regimens (ciprofloxacin, ofloxacin, norfloxacin, trimethoprim‐sulfamethoxazole, nitrofurantoin)
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Not using a diaphragm
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Treatment for > or = 3 days
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Pathogen not 'other'
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Symptom duration of < 2 days
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: K. pneumoniae
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: 'Other' pathogens
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Presence of pyuria (> or = 10 WBCs per high‐power field)
Number of subjects: 3108
Study: 7725851

Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-Ase) with human antithrombin III (AT III) concentrates as adjuvant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-asparaginase (L-Ase)
Number of subjects: 0
Study: 1971596

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 7458684

Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg daily
Number of subjects: 32
Study: 31759909

Group type: EXPERIMENTAL
Intervention: 15 g of a legume-based food product administered daily for three months (5 days on, 2 days off)
Number of subjects: 60
Study: 30704463

Group type: EXPERIMENTAL
Intervention: Bupivacaine (B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (LB)
Number of subjects: 58
Study: 27715376

Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 25194004

Group type: EXPERIMENTAL
Intervention: Paricalcitol (1 μg/d for 3 months, uptitrated to 2 µg/d if tolerated)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nonparicalcitol therapy
Number of subjects: 43
Study: 23514842

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 40 mg
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 80 mg
Number of subjects: 884

Group type: COMPARATOR
Intervention: Ramipril (RAM) 10 mg
Number of subjects: 884
Study: 21872682

Group type: COMPARATOR
Intervention: Secnidazole (2g)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mentha crispa (2g)
Number of subjects: 96
Study: 19413933

Group type: EXPERIMENTAL
Intervention: Mailed reminder two weeks prior to visit
Number of subjects: 5338

Group type: COMPARATOR
Intervention: No mailed reminder
Number of subjects: 5338
Study: 17942015

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg) administered at the start of each session during one therapy block
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo administered during the other therapy block
Number of subjects: 2
Study: 15157345

Group type: EXPERIMENTAL
Intervention: Low-dose risperidone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonrisperidone group (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study: 10690826

Group type: EXPERIMENTAL
Intervention: betaxolol-brinzolamide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: timolol-dorzolamide
Number of subjects: 25
Study: 9038596

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study: 8351830

Group type: EXPERIMENTAL
Intervention: Convex parabolic and concave parabolic shapes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbolic shapes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amount of curvature
Number of subjects: 0
Study: 2947101

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba Extract
Number of subjects: 0
Study: 30868570

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study: 30228265

Group type: EXPERIMENTAL
Intervention: Enzyme mixture containing peptidase, semi alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26430763

Group type: EXPERIMENTAL
Intervention: oPEP
Number of subjects: 27
Study: 24170759

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (targeting A1C <6.0%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glucose control (targeting A1C 7.0-7.9%)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 10251
Study: 22436365

Group type: EXPERIMENTAL
Intervention: 2006/07 group (n=43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 1993/96 group (n=40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 20200016

Group type: EXPERIMENTAL
Intervention: Episodic amiodarone treatment (1 month peri-cardioversion)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Continuous amiodarone treatment
Number of subjects: 158
Study: 18479924

Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal gravity conditions
Number of subjects: 0
Study: 15474654

Group type: EXPERIMENTAL
Intervention: Auditory perceptual training software
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no remediation program)
Number of subjects: 9
Study: 12756491

Group type: EXPERIMENTAL
Intervention: finasteride
Number of subjects: 18882

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18882
Study: 11185636

Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg with digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12
Study: 8607961

Group type: EXPERIMENTAL
Intervention: 100 micrograms of atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms of atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 micrograms of atropine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1440310

Group type: EXPERIMENTAL
Intervention: Allapinin, ethacizine, ritmilen, kinilentin, obsidan, and finoptin (given alone and in combinations)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combinations of drugs from the first group and those from the 2nd‐4th group
Number of subjects: 44
Study: 3988416

Group type: EXPERIMENTAL
Intervention: Soccer training with contract-relax stretching prior to beginning the session (B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Soccer training with stretching added at the end of the program (C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular soccer training (A)
Number of subjects: 48
Study: 30957448

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with sertraline hydrochloride (25 mg daily for the first 5 days, then 50 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sertraline hydrochloride (25 mg daily for the first 5 days, then 50 mg daily)
Number of subjects: 60
Study: 28199376

Group type: EXPERIMENTAL
Intervention: 6-PACK falls prevention program
Number of subjects: 120
Study: 25283680

Group type: EXPERIMENTAL
Intervention: Dependency
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Self-criticism
Number of subjects: 283
Study: 23470330

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicotine (in high symptomatic subjects)
Number of subjects: 24
Study: 20921964

Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER) - 2710 kJ/day for 2 days/week
Number of subjects: 107
Study: 18691778

Group type: EXPERIMENTAL
Intervention: Low potassium (<4 mEq/L)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Normal potassium (4-4.9 mEq/L)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Low-normal potassium (3.5-3.9 mEq/L)
Number of subjects: 561
Study: 16522906

Group type: EXPERIMENTAL
Intervention: Beta-glucan from oats
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (control) group with 5 g rice starch
Number of subjects: 47
Study: 14580051

Group type: EXPERIMENTAL
Intervention: Remifentanil/propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sufentanil/propofol
Number of subjects: 36
Study: 11389298

Group type: EXPERIMENTAL
Intervention: Draft CDC manual entitled, 'Guideline for Vaccine Storage and Handling'
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (did not receive copy of draft manual)
Number of subjects: 221
Study: 9209728

Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 101
Study: 7950119

Group type: EXPERIMENTAL
Intervention: diclofenac 0.1%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: flurbiprofen 0.03%
Number of subjects: 65

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study: 3313757

Group type: EXPERIMENTAL
Intervention: Ibuprofen/paracetamol/codeine combination (Myprodol; Rio Ethicals) 200 mg ibuprofen, 250 mg paracetamol, 10 mg codeine phosphate per tablet
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard ibuprofen treatment regimen (200 mg per tablet)
Number of subjects: 28
Study: 2242373

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 12
Study: 31655189

Group type: EXPERIMENTAL
Intervention: Oxycodone 15 mg (5 mg, eight hourly)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 155
Study: 29480399

Group type: EXPERIMENTAL
Intervention: Resistant dextrin (20g daily for 3 months)
Number of subjects: 62
Study: 28331306

Group type: EXPERIMENTAL
Intervention: Isometric contraction (IC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 22
Study: 25312754

Group type: EXPERIMENTAL
Intervention: 2-µm thulium laser (RevoLix, n=148)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 1.9-µm thulium laser (vela XL, n=148)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Both groups (2-µm and 1.9-µm lasers)
Number of subjects: 296
Study: 23167516

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with pulmonary rehabilitation (PRNS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 46
Study: 21503792

Group type: EXPERIMENTAL
Intervention: Methylene blue‐assisted lymph node dissection (MBLND)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional technique (Unstained)
Number of subjects: 50
Study: 18351337

Group type: EXPERIMENTAL
Intervention: Combined deferiprone (DFP) and deferoxamine (DFO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Daily deferiprone (DFP) only
Number of subjects: 66

Group type: COMPARATOR
Intervention: Deferoxamine (DFO) only 5 days/week
Number of subjects: 66
Study: 16551916

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (single shot)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia (continuous naropine infusion)
Number of subjects: 50
Study: 16465978

Group type: EXPERIMENTAL
Intervention: Supplementary food with added amylase-rich flour (ARF-SF)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard supplementary food (S-SF)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Supplementary food with added water (W-SF)
Number of subjects: 166
Study: 11159241

Group type: EXPERIMENTAL
Intervention: hyperbaric 5% lidocaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 58
Study: 9270289

Group type: EXPERIMENTAL
Intervention: Three counseling sessions in a prenatal setting
Number of subjects: 199

Group type: COMPARATOR
Intervention: Wallet-sized card listing community resources for violence
Number of subjects: 199
Study: 7942933

Group type: EXPERIMENTAL
Intervention: Unmodified niacin (up to 3,000 mg/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 28
Study: 2976727

Group type: EXPERIMENTAL
Intervention: hANP at 0.5 microgram/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hANP at 1.0 microgram/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hANP at 1.0 microgram/min (skin blood flow response)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 6
Study: 29769247

Group type: EXPERIMENTAL
Intervention: Aerobic and strength exercise programme
Number of subjects: 494

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 494
Study: 27782071

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strains (B632 and BR03) for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 40
Study: 24618460

Group type: EXPERIMENTAL
Intervention: Weight-reduction lifestyle program with soy-based meal replacement (LSMR)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Weight-reduction lifestyle program without meal replacement (LS)
Number of subjects: 380
Study: 22048987

Group type: EXPERIMENTAL
Intervention: Disco science (DS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No music (NM)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Achy breaky heart (ABH)
Number of subjects: 74
Study: 20459742

Group type: EXPERIMENTAL
Intervention: Training of household heads on the use of long-lasting insecticide-treated bed nets (LLITN)
Number of subjects: 4135

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 4135
Study: 18822403

Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Local anesthesia (1% lidocaine)
Number of subjects: 68
Study: 16792646

Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) in conjunction with a topical retinoid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Literature review on MDA
Number of subjects: 30
Study: 12808542

Group type: EXPERIMENTAL
Intervention: Needle placement using techniques from Gieringer and Delagi and Perotto
Number of subjects: 10
Study: 11487781

Group type: EXPERIMENTAL
Intervention: Primary closure (Group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional method (Group B)
Number of subjects: 106
Study: 9228878

Group type: EXPERIMENTAL
Intervention: G II knee brace
Number of subjects: 20
Study: 7966802

Group type: EXPERIMENTAL
Intervention: Perivalvular banding valvuloplasty (PVBV‐A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High ligation (HL‐A)
Number of subjects: 26
Study: 3313023

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASS) 2‐5 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunarizine 5‐10 mg
Number of subjects: 30
Study: 30742245

Group type: EXPERIMENTAL
Intervention: BI 853520 with food (high-fat meal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: BI 853520 as a liquid dispersion
Number of subjects: 16
Study: 28459407

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with fiberoptic bronchoscopy combined with vibration sputum drainage
Number of subjects: 286

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage with fiberoptic bronchoscopy
Number of subjects: 286
Study: 25844615

Group type: EXPERIMENTAL
Intervention: Topical sodium copper chlorophyllin complex (0.066%) applied twice daily for 8 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical sodium copper chlorophyllin complex (0.066%)
Number of subjects: 10
Study: 23579907

Group type: EXPERIMENTAL
Intervention: Tongue scraping
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tongue brushing
Number of subjects: 20
Study: 21372576

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 19
Study: 20040554

Group type: EXPERIMENTAL
Intervention: G. biloba 120 mg twice daily (n = 1545)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo (n = 1524)
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: G. biloba 120 mg twice daily
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study: 17605796

Group type: EXPERIMENTAL
Intervention: Ultra short stay programme
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 160
Study: 15497666

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 125 mg/5 mL (Klaromin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 250 mg/5 mL (Klaromin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14-hydroxy-clarithromycin
Number of subjects: 0
Study: 11673819

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HAART + ALVAC-HIV (vCP1452)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HAART + ALVAC-HIV (vCP1452) + Remune
Number of subjects: 148
Study: 9844553

Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 0
Study: 7986152

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 44
Study: 2590624

Group type: EXPERIMENTAL
Intervention: Riflux Forte
Number of subjects: 68

Group type: COMPARATOR
Intervention: Riflux
Number of subjects: 68
Study: 5420239

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 211

Group type: COMPARATOR
Intervention: Olive oil (Control)
Number of subjects: 211
Study: 31750676

Group type: EXPERIMENTAL
Intervention: Cash incentives ($1/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Charitable donations ($1/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 75
Study: 30380175

Group type: EXPERIMENTAL
Intervention: Left DLPFC tSMS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Right DLPFC tSMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tSMS
Number of subjects: 24
Study: 28970071

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 34
Study: 26454660

Group type: EXPERIMENTAL
Intervention: Social Phobia Inventory (SPIN)
Number of subjects: 397
Study: 23842584

Group type: EXPERIMENTAL
Intervention: Pressure Support (PSinit)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pressure Support (PSbest)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Number of subjects: 19
Study: 21945737

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ibandronate infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly oral alendronate
Number of subjects: 0